定义“代谢性”发作与“临床”、“生化”及“成骨细胞性”发作之间的相关参数，并制定评估癌症治疗反应的指南。 - Suppr

Suppr

超能文献

Defining co-related parameters between 'metabolic' flare and 'clinical', 'biochemical', and 'osteoblastic' flare and establishing guidelines for assessing response to treatment in cancer.

作者信息

Basu Sandip, Alavi Abass

出版信息

Eur J Nucl Med Mol Imaging. 2007 Apr;34(4):441-3. doi: 10.1007/s00259-006-0264-6.

DOI:10.1007/s00259-006-0264-6

PMID:17072613

Abstract

摘要

相似文献

Eur J Nucl Med Mol Imaging. 2007 Apr;34(4):441-3. doi: 10.1007/s00259-006-0264-6.

Restaging: should we percist without pattern recognition?

J Nucl Med. 2010 Dec;51(12):1830-2. doi: 10.2967/jnumed.110.079293. Epub 2010 Nov 15.

Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer?

Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1527-9. doi: 10.1007/s00259-007-0467-5.

18F-FDG imaging: pitfalls and artifacts.

J Nucl Med Technol. 2005 Sep;33(3):145-55; quiz 162-3.

Osteoblastic bone metastases in breast cancer: is not seeing believing?

Eur J Nucl Med Mol Imaging. 2005 Nov;32(11):1250-2. doi: 10.1007/s00259-005-1869-x.

[Therapeutic response evaluation by nuclear functional imaging].

Bull Cancer. 2007;94(7 Suppl):F241-4.

18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.

J Nucl Med. 2006 Jun;47(6):901-3.

Clinical PET in oncology.

Rev Esp Med Nucl. 2000 Jun;19(3):219-24.

Flare phenomenon in positron emission tomography in a case of breast cancer--a pitfall of positron emission tomography imaging interpretation.

Clin Imaging. 2009 Nov-Dec;33(6):468-70. doi: 10.1016/j.clinimag.2009.02.001.

Review of clinical practice utility of positron emission tomography with 18F-fluorodeoxyglucose in assessing tumour response to therapy.

Radiol Med. 2015 Apr;120(4):345-51. doi: 10.1007/s11547-014-0446-4. Epub 2014 Aug 26.

引用本文的文献

Pseudoprogression after advanced first-line endocrine therapy in metastatic breast cancer with bone metastasis: A case report.

Front Oncol. 2023 Jan 4;12:1099164. doi: 10.3389/fonc.2022.1099164. eCollection 2022.

Very Early Response Evaluation by PET/MR in Patients with Lung Cancer-Timing and Feasibility.

Diagnostics (Basel). 2019 Mar 26;9(1):35. doi: 10.3390/diagnostics9010035.

Quantitative contrast-enhanced CT attenuation evaluation of osseous metastases following chemotherapy.

Skeletal Radiol. 2017 Oct;46(10):1385-1395. doi: 10.1007/s00256-017-2706-6. Epub 2017 Jun 30.

Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.

Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1792-801. doi: 10.1007/s00259-016-3365-x. Epub 2016 Apr 12.

Critical considerations on the combined use of ¹⁸F-FDG and ¹⁸F-fluoride for PET assessment of metastatic bone disease.

Eur J Nucl Med Mol Imaging. 2013 Aug;40(8):1141-5. doi: 10.1007/s00259-013-2459-y. Epub 2013 May 22.

Single-fraction image-guided extracranial radiosurgery for recurrent and metastatic abdominal and pelvic cancers: short-term local control, metabolic response, and toxicity.

J Gastrointest Oncol. 2010 Sep;1(1):16-23. doi: 10.3978/j.issn.2078-6891.2010.010.

Osteoblastic response as a healing reaction to chemotherapy mimicking progressive disease in patients with small cell lung cancer.

Eur Radiol. 2009 Jan;19(1):193-200. doi: 10.1007/s00330-008-1115-6. Epub 2008 Aug 2.

[18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil.

Br J Cancer. 2007 Oct 8;97(7):902-9. doi: 10.1038/sj.bjc.6603971. Epub 2007 Sep 11.

本文引用的文献

Flare response in 18F-fluoride ion PET bone scanning.

AJR Am J Roentgenol. 2006 Jun;186(6):1783-6. doi: 10.2214/AJR.05.0225.

Is it time to incorporate quantitative functional imaging data, FDG PET in particular, into the response evaluation criteria in solid tumours?

Nucl Med Commun. 2006 May;27(5):413-6. doi: 10.1097/00006231-200605000-00001.

Use of PET for monitoring cancer therapy and for predicting outcome.

J Nucl Med. 2005 Jun;46(6):983-95.

FDG-PET in monitoring therapy of breast cancer.

Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S112-7. doi: 10.1007/s00259-004-1533-x. Epub 2004 Apr 27.

PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus.

J Nucl Med. 2004 Jan;45(1):56-68.

Is the flare phenomenon clinically significant?

Urology. 2001 Aug;58(2 Suppl 1):5-9. doi: 10.1016/s0090-4295(01)01235-3.

Metabolic flare: indicator of hormone responsiveness in advanced breast cancer.

J Clin Oncol. 2001 Jun 1;19(11):2797-803. doi: 10.1200/JCO.2001.19.11.2797.

Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia.

BJU Int. 2000 Apr;85(6):690-5. doi: 10.1046/j.1464-410x.2000.00528.x.

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Eur J Cancer. 1999 Dec;35(13):1773-82. doi: 10.1016/s0959-8049(99)00229-4.

Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.

Eur J Nucl Med. 1999 Jan;26(1):51-6. doi: 10.1007/s002590050359.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验